3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
5
Withdrawn
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
3
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Neurologic Manifestations
1
Lymphoma, Follicular
1
COVID-19
1
Interventions
Rituximab
129
Cyclophosphamide
122
Doxorubicin
62
Vincristine
61
venetoclax
58
Prednisone
57
ibrutinib
52
Specimen Handling
50
fludarabine
47
Lenalidomide
47
Biopsy
46
obinutuzumab
43
acalabrutinib
42
Etoposide
41
fludarabine phosphate
36
Magnetic Resonance Spectroscopy
36
Cytarabine
35
CT-P10
35
Dexamethasone
34
Methotrexate
29
Bendamustine Hydrochloride
27
pembrolizumab
26
Nivolumab
22
blinatumomab
21
zanubrutinib
20
prednylidene
19
Calcium Dobesilate
19
deltacortene
18
Radiotherapy
18
Melphalan
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Atorvastatin
×
Lymphoid
×
Clear all
NCT04904536
2025-04-10
STRONGER
The George Institute
Phase 3
Active not recruiting
190 enrolled